Heart attack while on Repatha? Amgen will give you your money back
Washington, DC —Amgen has overcome one of the toughest challenges in cardio research, outlining a clear health benefit for its PCSK9 cholesterol drug Repatha. But before payers get a chance to gnaw at the numbers being put on display today, looking for holes or finding fault with the level of benefit, the pharma giant wants to send them a simple message: it’s ready to offer a negotiated truce to get them to drop their defenses and pull out of the trenches.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
